肾移植后复发性C3肾病与原发性免疫复合物介导膜增生性肾小球肾炎的自然史与进展
这项多国回顾性队列研究纳入134例肾移植后活检证实的复发性C3G或原发性IC-MPGN患者,中位随访62个月,58%发生移植物丢失。时间平均蛋白尿>1 g/d和eGFR年下降>5 ml/min/1.73 m²可识别高风险轨迹,补体自身抗体阳性者移植物丢失更早。
要点
- 复发性C3G/IC-MPGN移植后预后差,58%移植物丢失。
- 时间平均蛋白尿>1 g/d和eGFR年降>5 ml/min/1.73 m²提示高风险。
- 补体自身抗体阳性者移植物丢失更早,支持个体化监测。
核心结论
- 复发性C3G和原发性IC-MPGN肾移植后长期结局差,组织学损伤重且生物学异质性显著。
- 纵向eGFR和蛋白尿提供强预后信息,特定阈值可细化风险分层。
研究设计与样本
- 多国回顾性队列研究,纳入2001-2023年48个中心11个国家的成人和儿童肾移植受者。
- 纳入标准为活检证实的复发性C3G或原发性IC-MPGN,且复发后至少有4次连续eGFR和蛋白尿测量。
- 采用线性混合效应和贝叶斯联合纵向-生存模型分析eGFR和蛋白尿轨迹与移植物失败的关系。
- 部分患者进行了补体遗传学和自身抗体检测。
主要发现
- 332例合格受者中134例发生活检证实的复发,其中C3GN占60%、致密沉积病占12%、IC-MPGN占28%。
- 复发中位时间为16个月,中位随访62个月后58%进展至移植物失败。
- 更早复发、较低血清白蛋白和较高组织学慢性化指数独立预测移植物失败。
- 联合模型显示较低eGFR和较高蛋白尿与更高移植物失败风险动态相关。
- 71例检测患者中34%携带致病性补体变异,23%有补体定向自身抗体;自身抗体阳性者移植物失败更早,但总体失败率相似。
关键数值与推荐
- 时间平均蛋白尿>1 g/d和eGFR年下降陡于-5 ml/min/1.73 m²可识别高风险轨迹。
临床怎么用
- 对复发性C3G/IC-MPGN肾移植受者,应纵向监测eGFR和蛋白尿,关注时间平均蛋白尿>1 g/d和eGFR年降>5 ml/min/1.73 m²的高风险阈值。
- 补体自身抗体检测可能有助于识别移植物丢失更早的高危患者,支持个体化随访。
局限性
- 回顾性研究设计。
- 补体遗传和自身抗体检测仅在部分患者中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In 134 kidney transplant recipients with recurrent C3 glomerulopathy/immune complex-mediated membranoproliferative GN, 58% lost the graft, confirming the poor long-term prognosis. Time-averaged proteinuria >1 g/d and eGFR decline >5 ml/min per 1.73 m 2 per year predicted higher graft failure risk. Complement profiling showed heterogeneity; autoantibody-positive patients lost grafts earlier, supporting personalized care. BACKGROUND: C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative GN (IC-MPGN) frequently recur after kidney transplantation and represent leading causes of graft loss. However, the natural history of recurrent disease and the prognostic value of longitudinal kidney biomarkers remain poorly defined. METHODS: We conducted a multinational, retrospective cohort study of adults and children with biopsy-proven recurrent C3G or primary IC-MPGN in the kidney allograft (2001-2023). Patients were enrolled from 48 centers across 11 countries and required ≥4 serial measurements of eGFR and proteinuria after recurrence. Longitudinal trajectories of eGFR and proteinuria and their association with graft failure were evaluated using linear mixed-effects and Bayesian joint longitudinal-survival models. Complement genetic and autoantibody testing was performed in a subset of patients. RESULTS: Of 332 eligible transplant recipients, 134 developed biopsy-proven recurrence (C3GN 60%, dense deposit disease 12%, IC-MPGN 28%). The median time to recurrence was 16 months, and 58% progressed to graft failure after a median follow-up of 62 months. Earlier recurrence, lower serum albumin, and higher histologic chronicity independently predicted failure. Joint models demonstrated that lower eGFR and higher proteinuria were dynamically associated with higher graft failure risk. Time-averaged proteinuria >1 g/d and eGFR lowering steeper than -5 ml/min per 1.73 m 2 per year identified high-risk trajectories. Among 71 tested patients, 34% carried pathogenic complement variants and 23% had complement-directed autoantibodies; autoantibody-positive patients experienced earlier graft failure despite similar overall failure rates. CONCLUSIONS: Recurrent C3G and primary IC-MPGN after transplantation are associated with poor long-term outcomes, substantial histologic injury, and marked biologic heterogeneity. Longitudinal eGFR and proteinuria provide powerful prognostic information and clinically meaningful thresholds (>1 g/d time-averaged proteinuria; eGFR slope steeper than -5 ml/min per 1.73 m 2 per year) refine risk stratification. Dynamic biomarkers may serve as surrogate end points, underscoring the need for prospective validation with emerging proximal complement therapies.
引用
- Ruiz-Cabello JE, Yandian F, Torres IB, et al. Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation. Clin J Am Soc Nephrol. 2026. PMID: 42462202. doi:10.2215/CJN.0000001117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。